This article is more than 5 years old. Information may no longer be current.
Highly accessed articles about SLE highlight treatments, risk factors
Click Here to Manage Email Alerts
Recent articles about systemic lupus erythematosus on Healio.com/Rheumatology highly accessed by readers included synapses of research about treatments in the pipeline and disease risk factors.
Other topics of interest included disease pathogenesis and disease criteria.
Several risk factors associated with damage progression identified in patients with SLE
Results recently published in The Journal of Rheumatology identified multiple risk factors, some of which are modifiable, associated with damage progression in patients with systemic lupus erythematosus (SLE). Read more.
SLE severity index using only ACR criteria may be reliable
An analysis of data from patients with SLE from the Lupus Family Registry and Repository shows that the development of a disease severity index that relies solely upon American College of Rheumatology (ACR) criteria may be a reliable indicator of disease activity. Read more.
Epratuzumab seen as well-tolerated, steroid-sparing treatment for up to 3.2 years in SLE patients
Treatment of moderate to severe SLE with epratuzumab infusions was well tolerated and associated with sustained improvements in disease activity and health-related quality of life. The treatment was also associated with reduced steroid use, according to an analysis of data from an open-label extension trial. Read more.
Silverman talks new treatments, pathogenesis of SLE
NEW YORK CITY— The elimination of B cells may be the key to controlling disease activity for patients with SLE, although the disease is heterogeneous, according to a speaker at the Interdisciplinary Autoimmune Summit. Read more.
Sifalimumab may improve symptoms in adult patients with SLE
Sifalimumab, an anti-interferon-alpha monoclonal antibody, may be effective for the treatment of some patients with SLE, according to recently published study data. Read more.
Response to cyclophosphamide may have genetic link for patients with lupus nephritis
The FCGR2B-FCRLA locus was associated with response to treatment with cyclophosphamide by patients with lupus nephritis, according to results of a study in which investigators used a genome-wide association approach. Read more.